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Ibrutinib (Imbruvica™) for Treatment of Mantle Cell Lymphoma
Brittany Crowe, fifth-year pharmacy student from New Springfield, Ohio; Joy Hoffman, fourth-year pharmacy student from
Fremont, Ohio; Hannah Stewart, fourth-year pharmacy student from Brazil, Ind.; Alison Steinbrunner, fifth-year pharmacy
student from New Carlisle, Ohio; Mark E. Olah, Ph.D., associate professor of pharmacology, chair of the department of
pharmaceutical and biomedical sciences

This knowledge-based activity is targeted for all pharmacists
and is acceptable for .5 hour (.05 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-14-173-HO 1-P

Objectives
After completion of this program, the reader should be able
to:
1. Identify current first-line treatments for mantle cell
lymphoma (MCL) when considering functional status
of the patient and stage of the cancer.
2. Explain the importance of MCL cell migration, as
seen in ex vivo study of ibrutinib.
3. Describe the pharmacology of ibrutinib.
4. Discuss the benefits of ibrutinib treatment in relapsed/refractory MCL observed in phase II development.
5. State key patient counseling points, including side
effects and dosing ofibrutinib for MCL.

Abstract
Mantle cell lymphoma (MCL) is a rare and moderately aggressive form of non-Hodgkin's lymphoma (NHL) that predominantly presents at an advanced stage in older males.
Patients often present with multiple involvement in the
lymph nodes, blood, spleen, bone marrow and gastrointestinal tract (GIT). Some patients may be asymptomatic in early
stages or present with an incurable, indolent (slow progressing) form, while other patients display rapid growth of more
aggressive lymphomas. Overall survival for patients diagnosed with MCL is four to five years and treatment should be
initiated in those who are symptomatic. Mantle cell lymphoma responds well to first-line treatment, but recurrent
relapses are common, and no regimen has been proven superior for relapsed or refractory MCL. The U.S. Food and Drug
Administration (FDA) has recently approved ibrutinib
(lmbruvica™) as breakthrough MCL therapy. lbrutinib is a
Bruton's tyrosine kinase (BTK) inhibitor that interferes with
malignant B-cell proliferation and survival. In a recent clinical study, ibrutinib proved to be a highly active monotherapy
with a favorable toxicity profile in 111 patients with relapsed
or refractory MCL. As an oral chemotherapy drug, ibrutinib
has the potential to improve patient compliance. Additionally, specialty pharmacies dispensing ibrutinib will be able to
play an important role in patient counseling and monitoring.
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Introduction to Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare form of NHL with
about 4,000 new cases each year in the United States.1.2 Most
patients with MCL present at the advanced stages, stage lII
and IV, with lymphadenopathy that is generalized and not
bulky. 1 The lymphoma will likely affect multiple tissues and
organs including lymph nodes, blood, spleen, and bone
marrow, and lymphomatoid polyposis, which are lymphoid
polyps in the gastrointestinal tract (GIT), may be present.3
Clinically, a patient with MCL may present with enlarged
lymph nodes, swollen abdomen, chest pain or pressure, or
satiety after a small amount of food due to enlarged tonsils,
liver or spleen. Presentation may also include dyspnea, fever,
unexplained weight loss, nausea and vomiting, fatigue due to
anemia or drenching night sweats.2,4 MCL presents most
commonly at a moderately aggressive stage in men in their
fifth and sixth decades of life.1
If a patient presents with suspected MCL, a tumor biopsy is

performed to confirm diagnosis. 1 An MCL biopsy lacks blastic
cell involvement, but otherwise resembles other lymphomas.
Cyclin Dl overexpression, elevated lactate dehydrogenase,
and beta-2 microglobulin may assist in diagnosis of MCL.S
Overexpression of cyclin Dl, a promoter of cell cycle progression, is present in up to 90 percent of MCL cases, due to a
(11;14) chromosomal translocation involving IgH and cyclin
Dl loci. 3 Elevated levels of lactate dehydrogenase and beta-2
microglobulin are present in 25 to SO percent of patients
with MCL.S,6 About 20 percent of MCL patients will progress
to an incurable, indolent lymphoma, accompanied by the
rapid growth of aggressive lymphomas.I This unique presentation of MCL contributes to a general life expectancy of four
to five years past the diagnosis. Patients in this stage will
often present similarly to chronic lymphocytic leukemia
(CLL), having a lymphadenopathy that is slow to progress
and a low tumor count.7 If asymptomatic, the patient should
be observed; however, in symptomatic patients who present
with bulky lymphadenopathy or splenomegaly, constitutional symptoms, or present with cytopenia requiring transfusion, treatment is required.
Current Treatments
First-line treatments for MCL vary according to the physical
status of the patient. Stem cell transplants are the first-line
treatment for patients who are younger than 65 years and
have good performance status, as they are more likely to tolerate this intensive treatment.7 These patients receive highdose chemotherapy (HDT), including Ara-C and rituximab,
followed by an autologous stem cell transplantation (ASCT).1
In eligible patients, this treatment is recommended once, and
provides a longer time to treatment failure (TTF) and im-
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proved overall survival (OS) as compared to protocols that
do not utilize rituximab.
Many patients, however, present at late stages of MCL and/or
may not be eligible for a transplant. 1 Radiation therapy is
usually ineffective at late stages and, therefore, chemotherapy is the mainstay of treatment. 7 Generally, patients receive
the R-CHOP regimen, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.1 This
therapy increases overall response rate (ORR), the percentage of patients whose cancer responds favorably to the
treatment, and complete response (CR) in which all signs of
cancer are eliminated due to treatment, but there is no improvement in os.1.a While other treatment regimens are
available, R-CHOP therapy has the best evidence.1
First-line treatments for MCL are often successful, but nearly
all patients will relapse within two years.1 The high relapse
rate has directed research to identify novel therapies. While
no regimen has yet been shown superior, many agents are
currently undergoing clinical trials. Bortezomib is a proteosome inhibitor with an ORR of 33 percent.21.7 Temsirolimus and other mammalian target of rapamycin (mTOR)
inhibitors are also being studied and have an ORR of 22 percent. Lenalidomide is an immunomodulator with an ORR of
53 percent. Jbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor with an ORR of 68 percent, CR of 22 percent, and partial response (PR), a decrease in tumor size or cancer extent
due to treatment, of 46 percent. Jbrutinib was recently FDA
approved for the treatment of relapsed MCL and is the focus
of this article.9
Ibrutinib Pharmacology and Pharmacokinetics
lbrutinib was approved in November 2013, for treatment of
MCL in patients who have been treated at least once previously.9 Jbrutinib was also approved in February 2014, for
chronic lymphocytic leukemia in patients who have received
one prior therapy.10 This paper will focus on the indication
for MCL, which was approved via the accelerated approval
program, as ibrutinib received breakthrough therapy designation.9,11 Ibrutinib inhibits BTK, a terminal non-receptor
tyrosine kinase, which promotes downstream activity of
growth factors, 8-cell antigens, chemokines and innate
immune receptors. 12 Normally, BTK signaling promotes
development, differentiation, and functioning of 8-cells. By
inhibiting BTK, ibrutinib inhibits proliferation of the lymphoma in MCL.

Ibrutinib inhibits kinase activity of BTK through covalent
binding to the non-catalytic cys-481 residue of BTK, which is
present in only 10 other kinases at this exact position. 13
Therefore, ibrutinib is a fairly selective inhibitor of BTK, being 1,000 times more selective for BTK of 8-cells than CD69
of T-cells. Ibrutinib irreversibly inhibits BTK-driven gene
expression. When compared with a known reversible inhibitor of BTK, ibrutinib inhibited gene up-regulation following a
washout period while the reversible inhibitor did not. In vitro, one-hour exposure compared to continuous exposure to
ibrutinib has the same inhibitory activity, demonstrating that
one-time exposure is sufficient to inhibit BTK. Ibrutinib is
July 2014 Volume 5, Issue 3
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relatively potent with an JCso of 0.5 nM.
In vitro, ibrutinib appears to induce apoptosis of B-cells by
two main mechanisms: inhibiting anti-apoptotic mechanisms
and stimulating pro-apoptotic mechanisms. First, ibrutinib
blocks anti-apoptotic pathways by decreasing ERK phosphorylation, decreasing NF-kB signaling, and decreasing expression of Akt, a serine threonine kinase that promotes cell
cycle progression.14-18 Secondly, ibrutinib stimulates proapoptotic mechanisms in B-cells by activating caspases.14
Additionally, ibrutinib decreases anti-JgM-induced signaling
that stimulates B-cells by decreasing adhesion to VCAM, an
adhesion molecule, and fibronectin, a glycoprotein involved
in adhesion and migration.11,19,20 Ibrutinib also decreases
signaling induced by chemokines such as CXCL-12 and CXCL13, that are secreted by stromal cells, and decreases production of cytokines such as interleukin-10.1s,11,21 By interfering
with this signaling, ibrutinib inhibits the migration, adhesion,
and proliferation of malignant B-cells.
The cellular mechanisms of ibrutinib that were delineated in
vitro were substantiated in a study published by Chang and
colleagues. 22 This study provided ex vivo insight to the
mechanism of action of the anti-tumor effect of ibrutinib by
examining the migration of MCL cells from the tumor into the
peripheral blood and the characteristics of these malignant
cells once in the periphery. Phenotyping, adhesion molecule
assessments and migration assays were performed on blood
samples collected from 22 patients participating in ibrutinib
clinical trials. Following ibrutinib treatment, there was a statistically significant increase in the absolute lymphocyte
count (ALC) in the peripheral blood, demonstrating the migration of malignant cells to the periphery, which contributes
to the death of these cells. The lymphocytes tested, CDl 9 and
CDS, had a decreased expression of CXCR4, CD38, and Ki57,
all of which are surface molecules necessary for successful
cell cycle progression. lbrutinib suppressed the B-cell receptor (BCR)-stimulated cytokine and chemokine production
from MCL cells and inhibited BCR-stimulated adhesion of
MCL cells.
By inhibiting adhesion molecule expression, chemokine production and the downstream signaling of BTK, ibrutinib therapy forces malignant cells to migrate from their host tissue
and enter the peripheral blood.2 2 These micro events were
further documented at the macro level as the lymph tissue
mass clinically decreased. lbrutinib decreased expression of
CXCR4, a protein necessary for chemotaxis of malignant cells
back to preferred tissues. The entrance and maintenance of
malignant cells in the periphery is important because the
MCL cells meet their demise in the peripheral blood. In the
periphery, these cells do not have soluble factor exposure
and other necessary components for proliferation and survival, and consequently, the malignant cells die and are
cleared from the body. This study is important as it shows
the mechanisms of anti-tumor action of ibrutinib and provides micro level insight of the positive macro level clinical
results.
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Pharmacokinetic studies on ibrutinib have also been conducted. Without food, the T max of ibrutinib is approximately
one to two hours, with an area under the curve (AUC) of
953 ng*h/mL at steady state.23 In the body, the drug is highly
protein bound, evidenced by a volume of distribution of
10,000 L at steady state. Ibrutinib is primarily metabolized
by CYP3A4, with some metabolism via CYP206. The half-life
of ibrutinib is four to six hours, and the majority of metabolites are excreted in feces.
Clinical Study
A phase II open-label, non-randomized, multicenter, monotherapy study by Wang and colleagues investigated the use
of oral ibrutinib in 111 patients with relapsed or refractory
MCL.2 4 Other clinical trials are currently in progress, but the
accelerated approval of ibrutinib was based on this trial.9,25
The study enrolled subjects into two cohort groups based on
their treatment history. 24 The first group included subjects
who had previously received at least two, but not more than
five, cycles of bortezomib therapy, while the second group
included those who had received less than two complete cycles or no prior bortezomib therapy. Eligible patients were
required to have a confirmed diagnosis of MCL. Diagnosis
was based on either cyclin 01 overexpression or chromosomal translocation break points and an increase in lymph
node diameter as a measure of staging the disease.
The primary end point was ORR, defined as the proportion of
study subjects who achieved either complete or partial remission as their best overall response as defined by the
modified Revised Response Criteria for Malignant
Lymphoma.24, 26 According to the Response Criteria, complete
remission was the disappearance of all evidence of disease,
and partial remission was regression of measurable disease
with no new sites.27 Efficacy, safety, pharmacokinetics, and
patient-reported outcomes regarding quality of life were all
considered as secondary end points. 26 Subjects received
560 mg of oral ibrutinib daily in 28-day cycles until progression of the disease or an unacceptable level of adverse events
was observed.24 The timing of patient visits and assessments
were based on the treatment cycles.26
The response rate for all patients was 68 percent, which included a partial response in 4 7 percent of subjects and a
complete response in 21 percent.24 The response rate did not
vary with baseline characteristics or risk factors among the
111 subjects. Based on near equivalence of response between the two cohorts, the ORRs were reported together as a
single percentage. The median time to a response was 1.9
months, the estimated median response duration was 17.5
months, and the estimated median progression-free survival
was 13.9 months among all treated. The National Cancer Institute's Common Terminology Criteria for Adverse Events
version 4.0 were used to evaluate adverse events.26 The criteria include a scale of grades corresponding with the severity of adverse events: grade 1 (mild), grade 2 (moderate),
grade 3 (severe or medically significant but not immediately
life threatening), grade 4 (life threatening), and grade 5
(death related to adverse events).28 The majority of the adverse events observed with ibrutinib treatment were classi-
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fled as grade 1 or grade 2, while grades 3, 4 and 5 were uncommon.24 Over 20 percent of patients experienced mild side
effects such as diarrhea, fatigue, nausea, peripheral edema,
dyspnea, constipation, upper respiratory tract infection,
vomiting and decreased appetite.
Peripheral blood lymphocytes were characterized postibrutinib treatment, and it was found that 34 percent of subjects had an increase in ALC that decreased and then tapered
off by cycle 4 or cycle 5.24 The increase included mostly
CD19+CD5+CD3- lymphocytes with a pattern of light chain
restriction that is consistent with MCL cells in peripheral
blood. Investigators also found that ibrutinib caused a decrease in the secretion of macrophage inflammatory proteins
1-alpha (CCL3) and 1-beta (CCL4 ), macrophage-derived
chemokine (CCL22) and TNF-alpha in most patients.
In a separate study, Chang and colleagues effectively demonstrated the ability of ibrutinib to inhibit the adhesion of MCL
cells ex vivo, resulting in their mobilization to the peripheral
blood. 22 Similar inhibitory effects were observed with in vitro ibrutinib treatment for CLL. 29 Wang and colleagues cited
these findings as part of their reasoning for investigating the
presence of MCL cells in the peripheral blood of study subjects. The ex vivo analysis, conducted by investigators within
the in vivo study, also indicated that ibrutinib caused a transient increase in blood lymphocytes as well as a decrease in
the secretion of certain inflammatory molecules.24 Therefore,
the phase II trial by Wang and colleagues demonstrates the
benefit of ibrutinib treatment on a micro level in study subjects who also exhibited favorable macro level effects such as
high response rate accompanied with a favorable level of
toxicity. These effects indicate that ibrutinib has the potential
to be a less intensive but more effective regimen than other
treatments available for relapsed and refractory MCL.
Investigators in this phase II trial concluded that ibrutinib is
a highly active, single agent with considerable duration of
activity in relapsed and refractory MCL along with a favorable toxicity profile.24 A major strength in the study design
was the combination of two cohorts that allowed representation of a broad population of subjects with relapsed or refractory MCL within a moderately small sample size. Patients
receiving ibrutinib demonstrated statistically and clinically
significant data indicating the potential for ibrutinib as a new
treatment for relapsed and refractory MCL.

Pharmacist Focus
Dosing for ibrutinib is 560 mg daily, which equates to four
140 mg capsules once daily. Dosing is based on evidence
from the previously discussed clinical trial.24 lbrutinib may
cause fetal harm in pregnant women and secretion into
breast milk is unknown, as therapy should be carefully considered in the affected population.23 Concurrent CYP3A inducers should be avoided, as they can decrease the plasma
concentration of ibrutinib. Concurrent CYP3A4 inhibitors
increase the risk of toxicity by increasing the AUC and Cmax of
ibrutinib, and ibrutinib should be discontinued if short-term
therapy with a CYP3A4 inhibitor is utilized.
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An advantage of ibrutinib is a more favorable adverse effect
profile for certain patient populations in comparison to other
agents for relapsed MCL including bortezomib, temsirolimus
and lenalidomide. The more severe adverse effects of these
drugs include profound myelosuppression, anemia, cardiac
effects, metabolic acidosis and hepatotoxicity.30-32 Serious
adverse effects of ibrutinib include hemorrhage, infections,
myelosuppression, renal toxicity and risk of secondary primary malignancies.23 While ibrutinib still exhibits serious
adverse effects, it is a preferred choice for patients who have
cardiac or hepatic complications.

3.
4.

5.

6.
7.

Being an oral chemotherapy agent, ibrutinib has many benefits acknowledged by health care providers. These benefits
include patient convenience and comfort, more favorable
risk-benefit profiles and the availability of specialty pharmacies to help with reimbursement challenges and financial
assistance and are among the top reasons oncologists would
be more likely to prescribe an oral chemotherapy agent over
an intravenous (IV) agent.33,34
Another benefit of oral ibrutinib is the ability of patients to
utilize outpatient services to obtain the medication. In regard
to outpatient pharmacy services, specialty pharmacies, as
previously mentioned, are expected to be often utilized.
While their place in care is evolving, specialty pharmacies are
essentially "niche" pharmacies.35 As defined by Scott Kober,
"[Specialty pharmacy] serve[s] a limited number of patients
with a small number of high-cost, low-volume and highmaintenance conditions .... "35 These pharmacies offer special
services such as high-quality counseling and assistance in
navigating payment options for treatment.34,36 As an oral
chemotherapy agent, ibrutinib will likely be frequently dispensed at specialty pharmacies.

8.

9.
10.

11.

12.
13.

14.

15.

16.

Conclusion
There is a need for effective chemotherapy agents that can be
used to treat relapsed or refractory cases of MCL. Molecularly targeted drugs such as bortezomib, temsirolimus and
lenalidomide have shown anti-lymphoma activity useful in
treating difficult cases of MCL.6 As a BTK inhibitor, ibrutinib
also works on a molecular level to interfere in the malignant
8-cell signaling cascade.6.22 Clinical trials have shown impressive response rates for this newly introduced therapy.24
Treatment with ibrutinib offers advantages including oral
route of administration and a favorable toxicity profile compared to other more intensive treatments. Furthermore,
some oncologists have indicated that they prefer oral chemotherapies over IV regimens, with one reason being the role
that specialty pharmacies may then take in optimizing patient care through counseling and monitoringJ.33,34 Although
MCL is a moderately aggressive form of NHL, high response
rates with ibrutinib therapy offers patients a chance for progression-free survival when first-line therapies have failed.
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Assessment Questions
1.

2.

3.

4.

5.

KL is a 68 year old male with poor functional status who
has recently been diagnosed with late stage MCL. He is
about to start his first treatment. Which of the following
is the most appropriate treatment regimen for him?
A. External beam radiation therapy
B. Ibrutinib x 28 day trial
C. Rituximab + cyclophosphamide + doxorubicin +
vincristine + prednisone (R-CHOP)
D. Stem cell transplantation
E. More than one of the above
Which of the following CORRECTLY describes the importance of MCL cell migration?
A. By inhibiting adhesion molecule expression,
MCL cells are forced to enter peripheral blood.
B. Ibrutinib decreases expression of CXCR4, which
prevents malignant cells' return to their tissues.
C. Once in the periphery, MCL cells do not have the
necessary components for survival and die.
D. Two of the above
E. Three of the above
TR is a 57 year old female coming to your specialty pharmacy. She has arrived to pick up her new prescription
for ibrutinib to treat her relapsed MCL. While excited
that there are no needles involved with this drug, she is
nervous about starting the new treatment and any adverse effects it might bring. What counseling points
about the adverse effects do you offer her?
A. "You may bleed more easily. Take care to avoid
injury."
B. "If you feel very tired or weak, have an upset
stomach, have a fast heartbeat or are breathing
fast, call your doctor. These may be signs of too
much acid in your blood."
C. "This drug makes you more likely to catch illnesses, such as the flu or a cold. Stay away from
people who are sick."
D. Two of the above
E. Three of the above
lbrutinib works by inhibiting which protein?
A. Proteasome
B. CDZO
C. Bruton's tyrosine kinase
D. Epidermal growth factor receptor
E. Cyclin Dl
What is the dosing of ibrutinib for MCL?
A. 560 mg daily
B. 140 mgTID
C. 560 mg BID
D. 280 mg daily
E. 280 mg BID
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6.

Which enzyme is primarily responsible for ibrutinib's
metabolism?
A. CYP2C19
B. VKOR
C. CYP2A9
D. CYP3A4
E. Ibrutinib is excreted unchanged in urine

7.

Which of the following statements accurately describes
the toxicity profile associated with ibrutinib:
A. Ibrutinib is not associated with a high occurrence of severe side effects such as grade 4 hemorrhagic events.
B. Patients taking ibrutinib most commonly experience grade 1 or 2 adverse events.
C. Possible side effects of ibrutinib include diarrhea, fatigue, dyspnea, and decrease in appetite.
D. Two of the above
E. Three of the above

8.

What were the major advantages associated with
ibrutinib treatment in the main phase II clinical trial utilized for accelerated FDA approval?
A. All participants achieved a complete response.
B. Ibrutinib was found to be a highly active, single
agent.
C. Ibrutinib therapy had a considerable duration of
action.
D. Two of the above
E. Three of the above

9.

During clinical development, both ex vivo and in vivo
research indicated that ibrutinib had the potential to be
a less intensive but more effective regimen than other
treatments currently available.
A. True
B. False

10. The protein target of ibrutinib normally has what function in a healthy body?
A. Induces apoptosis of B-cells
8. Stimulates chemokine release
C. Promotes B-cell development
D. Two of the above
E. Three of the above
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1

2

3

4

5

Identify current first-line treatments for mantle cell lymphoma (MCL)
when considering functional status of the patient and stage of the
cancer.

1

2

3

4

5

Explain the importance of MCL cell migration, as seen in ex vivo study
of ibrutinib.

1

2

3

4

5

Describe the pharmacology of ibrutinib.

1

2

3

4

5

Discuss the benefits of ibrutinib treatment in relapsed/refractory
MCL observed in phase II development.

1

2

3

4

5

State key patient counseling points, including side effects and dosing
of ibrutinib for MCL.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer
1.

A B

2. A B
3. A B

c
c
c

D E

4. A B

D E

5. A B

D E

6. A B

c
c
c

D E

7. A B

D E

8.

A B

D E

9.

A B

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for the
Office of Continuing Education (email : 1-hamman(c/'onu.edu, phone 419772-2280).

c
c

~-

D E

10. A B

c

D E

D E
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